AUROBINDO

May 18, 2012

NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E)
MUMBAI -400 051

Dear Sirs,

SUB: Press Release – Reg
Ref: Our Company Code No. AUROPHARMA

Please find enclosed herewith a copy of Press Release issued by the Company.

This is for your information and record

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

A.MOHAN RAMI REDDY
GM (Legal) & COMPANY SECRETARY

AUROBINDO

18th May 2012

Aurobindo Pharma receives final approval for Clopidogrel Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Clopidogrel Tablets USP 75 mg (ANDA 090540), which is being launched.

Clopidogrel Tablets USP 75 mg is the generic equivalent of Aventis US LLC (Sanofi)'s Plavix® Tablets USP 75mg. The product falls under the cardio-vascular (CVS) therapeutic category and is indicated for the prevention of atherothrombotic events in patients who have had a myocardial infarction or ischaemic stroke, or who have established peripheral arterial disease). The annual sale of the product is approximately US$ 6.4 billion

The product has been approved out of Unit III formulations facility in Hyderabad, India

Aurobindo now has a total of 151 ANDA approvals (123 Final approvals including 1 from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 125 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad
Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com